Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 736

1.

New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.

Poland GA, Fleming DM, Treanor JJ, Maraskovsky E, Luke TC, Ball EM, Poland CM.

Vaccine. 2013 Apr 17;31 Suppl 1:A1-20. doi: 10.1016/j.vaccine.2013.02.033.

PMID:
23587330
2.

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA.

Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30.

PMID:
22469860
3.

Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.

Rockman S, Brown LE, Barr IG, Gilbertson B, Lowther S, Kachurin A, Kachurina O, Klippel J, Bodle J, Pearse M, Middleton D.

J Virol. 2013 Mar;87(6):3053-61. doi: 10.1128/JVI.02434-12. Epub 2013 Jan 2.

4.

Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.

Ann J, Samant M, Rheaume C, Dumas C, Beaulieu E, Morasse A, Mallett C, Hamelin ME, Papadopoulou B, Boivin G.

Vaccine. 2014 Sep 29;32(43):5730-9. doi: 10.1016/j.vaccine.2014.08.029. Epub 2014 Aug 27.

PMID:
25173481
5.

Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models.

Park SJ, Kim EH, Pascua PN, Kwon HI, Lim GJ, Decano A, Kim SM, Song MK, Shin EC, Choi YK.

J Gen Virol. 2014 Apr;95(Pt 4):793-8. doi: 10.1099/vir.0.058636-0. Epub 2014 Jan 13.

PMID:
24421115
6.

Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.

Girard MP, Katz JM, Pervikov Y, Hombach J, Tam JS.

Vaccine. 2011 Oct 13;29(44):7579-86. doi: 10.1016/j.vaccine.2011.08.031. Epub 2011 Aug 19.

PMID:
21856358
7.

Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.

Maltais AK, Stittelaar KJ, Veldhuis Kroeze EJ, van Amerongen G, Dijkshoorn ML, Krestin GP, Hinkula J, Arwidsson H, Lindberg A, Osterhaus AD.

Vaccine. 2014 May 30;32(26):3307-15. doi: 10.1016/j.vaccine.2014.03.061. Epub 2014 Mar 30.

8.

Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.

Bragstad K, Martel CJ, Thomsen JS, Jensen KL, Nielsen LP, Aasted B, Fomsgaard A.

Influenza Other Respir Viruses. 2011 Jan;5(1):13-23. doi: 10.1111/j.1750-2659.2010.00177.x. Epub 2010 Nov 3.

9.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
10.

Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.

Vaccine. 2011 Dec 9;30(1):35-41. doi: 10.1016/j.vaccine.2011.10.062. Epub 2011 Nov 7.

PMID:
22063386
11.

Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.

Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM.

Vaccine. 2011 Aug 11;29(35):5911-8. doi: 10.1016/j.vaccine.2011.06.068. Epub 2011 Jun 30.

PMID:
21723354
12.

Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.

van de Sandt CE, Kreijtz JH, Geelhoed-Mieras MM, Vogelzang-van Trierum SE, Nieuwkoop NJ, van de Vijver DA, Fouchier RA, Osterhaus AD, Morein B, Rimmelzwaan GF.

Vaccine. 2014 Sep 29;32(43):5614-23. doi: 10.1016/j.vaccine.2014.08.003. Epub 2014 Aug 17.

PMID:
25140929
13.

A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.

Bodewes R, Kreijtz JH, van Amerongen G, Geelhoed-Mieras MM, Verburgh RJ, Heldens JG, Bedwell J, van den Brand JM, Kuiken T, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2010 Aug;84(16):7943-52. doi: 10.1128/JVI.00549-10. Epub 2010 Jun 2.

14.

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.

Banzhoff A, Haertel S, Praus M.

Hum Vaccin. 2011 May;7(5):539-48. Epub 2011 May 1.

PMID:
21422814
15.

Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.

Liu G, Song L, Reiserova L, Trivedi U, Li H, Liu X, Noah D, Hou F, Weaver B, Tussey L.

Vaccine. 2012 Nov 6;30(48):6833-8. doi: 10.1016/j.vaccine.2012.09.013. Epub 2012 Sep 18.

PMID:
23000130
16.

Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.

Kreijtz JH, Osterhaus AD, Rimmelzwaan GF.

Hum Vaccin. 2009 Mar;5(3):126-35. Epub 2009 Mar 15. Review.

PMID:
18948744
17.
18.

Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.

Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F.

Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20.

PMID:
22192847
19.

Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.

Baras B, de Waal L, Stittelaar KJ, Jacob V, Giannini S, Kroeze EJ, van den Brand JM, van Amerongen G, Simon JH, Hanon E, Mossman SP, Osterhaus AD.

Vaccine. 2011 Mar 3;29(11):2120-6. doi: 10.1016/j.vaccine.2010.12.125. Epub 2011 Jan 14.

PMID:
21238573
20.

Supplemental Content

Support Center